Comparison of Tailor X and NSABP-20 regarding cost-effectiveness of recurrence score (RS®) for adjuvant chemotherapy decision in early-stage breast cancer
Makaleler > Tam Makale · 2026
Yazarlar: Çetin Ordu, Enver Özkurt, Ertan Koç, Erhan GÖKMEN, Mustafa Özdoğan, Nilüfer Güler, Cihan Uras, Bahadır Öz, Abdurrahman Işıkdoğan, Orhan Demircan, Fulden Yumuk, Pınar Saip, Vahit Özmen
BMC Health Services Research, Uluslararası, Wos, 2026
DOI: 10.1186/s12913-026-15300-9
Özet
The aim of this study is to re-evaluate the decision of adjuvant chemotherapy according to TAILORx trial in our patients included in the prospective clinical study based on NSABP-20 criteria, and to recalculate the cost-effectiveness of ODX RS. Patients were analyzed for cost-effectiveness in the chemotherapy + endocrine therapy or endocrine therapy. The cost-effectiveness analyses of treatment before and after the ODX RS ® result were compared according to Tailor X. The deterioration in quality of life during chemotherapy was calculated based on the time the patient was away from daily activities, 6 months of work loss in 1 year and the cost of chemotherapy. ICER (ICER: Incremental Cost-Effectiveness Ratio) was calculated for cost-effectiveness. During a median follow-up period of 108.4 months (range 15.8–111), in 11 (6.7%) patients metastases were detected. Three patients (1.8%) died due to breast cancer. Among 92 patients who were scheduled for chemotherapy (CT) before the RS ® results were available, 41 were genomically low-risk and based on this findings were omitted from chemotherapy. According to the first study in which the chemotherapy decision was based on NSABP-20 18 patients (~ 20%) received unnecessary chemotherapy with the updated Tailor X criteria. Compared to a purely clinico-pathological assesment, a treatment based on ODX RS ® was found to be at least $1938 more cost-effective (0.68 QALYs). In conclusion, the Oncotype DX Recurrence Score (ODX RS ® ) test in Turkey was found to be cost-effective in HR(+) HER2(-) patients according to the updated TAILORx data for adjuvant chemotherapy decisions. Not applicable.